Place of 68Ga-PSMA-11 PET-CT in the Therapeutic Decision at the End of the Initial Staging for High Risk Prostate Cancer Patients

Central Hospital, Nancy, France33 enrolled

Overview

Several studies have shown a great potential of 68Ga-PSMA PET in high risk prostate cancers patients and a high detection rate than 18F-Choline PET. The primary aim of this study is to evaluate the difference of management intent, after the inital staging of high risk prostate cancer patients, with 68Ga-PSMA-11 PET-CT results in comparison of 18F-Choline PET-CT results.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Prostate Cancer

Interventions

68Ga-PSMA-11DIAGNOSTIC_TEST

radioactive tracer for PET-CT (68Ga-PSMA-11)

18F-Choline PET-CTDIAGNOSTIC_TEST

radioactive tracer for PET-CT (18F-Choline PET-CT)

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * high risk prostate cancer patients with initial tests : CT, bone scintigraphy and 18F-Choline Exclusion Criteria: * contraindication of 68Ga-PSMA PET-CT

Locations (1)

Central hospital Nancy

Nancy, France

Outcomes

Primary Outcomes

percentage of modification of management intent

modification of management intent after 68Ga-PSMA PET-CT and 18F-Choline PET-CT

Time frame: 1 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.